Siliq (brodalumab) / Kyowa Kirin, LEO Pharma, Bausch Health, AstraZeneca 
Welcome,         Profile    Billing    Logout  

18 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Siliq (brodalumab) / Bausch Health
2018-000097-30: Efficacy of brodalumab in patients with psoriasis with failure of other anti-IL-17 treatments Effekt af brodalumab hos patienter, som har haft svigt af anti-IL-17A-behandling

Ongoing
4
20
Europe
brodalumab, Solution for injection in pre-filled syringe, Kyntheum
Herlev and Gentofte Hospital, LEO Pharma A/S
Psoriasis Psoriasis, Psoriasis Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2018-001021-10: A Clinical study with brodalumab for patients suffering from psoriasis and not benefitting the TNF-alpha treatment.

Ongoing
4
90
Europe
Injection, Kyntheum
Sahlgrenska University Hospital, Leo Pharma Ab
Moderate to severe plaque psoriasis, Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2019-004230-42: Dose reduction of IL17 and IL23 inhibitors for psoriasis Dosis reductie van IL17 en IL23 remmers voor psoriasis

Not yet recruiting
4
244
Europe
secukinumab, ixekizumab, brodalumab, risankizumab, tildrakizumab, guselkumab, Injection, Cosentyx, Taltz, Kyntheum, Skyrizi, Ilumetri, Tremfya
Radboudumc, ZonMw, KCE
psoriasis psoriasis, psoriasis psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2021-003785-13: Trial to investigate efficacy of brodalumab in eczematized psoriasis

Not yet recruiting
4
15
Europe
Brodalumab, Injection, Brodalumab
Karolinska Universitetssjukhuset, Leo Pharma
eczematized psoriasis, Psoriasis with eczema like features, Diseases [C] - Immune System Diseases [C20]
 
 
NCT04622033: Brodalumab in Palmoplantar Psoriasis

Not yet recruiting
4
10
NA
Brodalumab
First OC Dermatology
Palmoplantar Psoriasis
11/21
05/22
BeNeBio, NCT04340076: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Active, not recruiting
4
244
Europe
Secukinumab, Cosentyx, Ixekizumab, Taltz, Brodalumab, Kyntheum, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tildrakizumab, Ilumetri, Bimekizumab, Bimzelx
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre, University Hospital, Ghent
Psoriasis, Psoriasis Vulgaris
12/25
12/25
ChiCTR2000039699: A Phase 4 Clinical Study to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy of Brodalumab (KHK4827) in Subjects with Moderate to Severe Plaque Psoriasis

Recruiting
4
400
 
Brodalumab Injection (KHK4827) 210 mg Q2W ;Placebo
Peking University People's Hospital; Kyowa Kirin Co., Ltd., self financing
The treatment of moderate to severe Plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
 
 
NCT03240809: An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Recruiting
4
16
US
Brodalumab
Bausch Health Americas, Inc.
Psoriasis
07/24
07/24
ADJUST, NCT04306315 / 2017-004998-13: Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

Recruiting
4
384
Europe, RoW
Brodalumab
LEO Pharma, LEO Pharma A/S
Psoriasis Vulgaris
09/25
01/26
NCT03957681: A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

Checkmark Safety and efficacy of LUMICEF in subjects with systemic sclerosis at EULAR 2022
Jun 2022 - Jun 2022: Safety and efficacy of LUMICEF in subjects with systemic sclerosis at EULAR 2022
Active, not recruiting
3
100
Japan
KHK4827, Placebo
Kyowa Kirin Co., Ltd.
Moderate to Severe Systemic Sclerosis
10/20
02/24
NCT04061252: A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

Completed
3
126
Japan
KHK4827, Placebo
Kyowa Kirin Co., Ltd.
Palmoplantar Pustulosis
08/21
08/22
EMBRACE 1, NCT04305327 / 2019-001868-30: Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis

Terminated
3
12
Europe
Brodalumab, Kyntheum®, Ustekinumab, Stelara®, Placebo
LEO Pharma
Psoriasis
05/23
05/23
NCT04368403: A Study of KHK4827 in Patients With Systemic Sclerosis

Active, not recruiting
1
8
Japan
KHK4827
Kyowa Kirin Co., Ltd.
Systemic Sclerosis
01/19
02/24
BOMOGUMIP, NCT04680624: Role of Brodalumab in the Modulation of Gut Microbiome in Psoriatic Patients

Not yet recruiting
N/A
15
NA
Fecal sample collection
Association pour la Recherche Clinique et Immunologique
Psoriasis
01/22
01/22
BIOLOPTIM-BRO, NCT04080635: Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients

Recruiting
N/A
100
Europe
Venapuncture, Patient questionnaires
University Hospital, Ghent, KU Leuven, University Ghent
Psoriasis Vulgaris
12/24
12/24
CARE, NCT05132231: Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

Recruiting
N/A
500
Canada
Brodalumab, Matched cohort
Bausch Health Americas, Inc.
Psoriasis
06/24
06/24
NCT03358693: Molecular Signatures in Inflammatory Skin Disease

Recruiting
N/A
300
Europe
Ustekinumab, Infliximab, Secukinumab, Dupilumab, Brodalumab, Ixekizumab, Baricitinib, Abrocitinib, Upadacitinib, Tralokinumab
Prof. Dr. Stephan Weidinger
Atopic Dermatitis, Psoriasis
12/27
12/28
NCT03254667: LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Enrolling by invitation
N/A
3500
US
Brodalumab, Comparator Drug (non-biologic IL-17 inhibitors)
Bausch Health Americas, Inc.
Psoriasis
11/30
11/31

Download Options